Congratulations to Margo Waters of the Nallathamby lab for having being selected for the Inaugural Woodward family endowment for excellence in NDnano undergraduate research! Margo has been an exceptional contributor to advancing research on novel cancer therapeutics in our lab. You can check out more about what motivates her at https://research.nd.edu/news/inaugural-woodward-family-endowment-for-excellence-in-ndnano-undergraduate-research-awarded/
Category Archive: AD&T Notre Dame
Jul 02
Inaugural Woodward family endowment for excellence in NDNANO undergraduate research awarded to Margo Waters
Categories:
AD&T Notre Dame, Berthiaume Institute for Precision Health, Cancer stem cells, Combination chemotherapy, Harper Cancer Research Institute, metastatic cancer cells
by Prakash
Tags: NDNano
Recent Posts
- Military Health Sciences Research Symposium 2024. (Aug 26-29, 2024, Kissimmee FL) August 30, 2024
- Sustained and Controlled Antibiotics Release for Prolonged Antibacterial Action Against MRSA, and Pseudomonas aeruginosa August 21, 2024
- Precision Health and Diagnostics Session Chair at Techconnect World Innovation Conference (2024) June 19, 2024
- MTEC Annual meeting in Baltimore MD (May 24, 2024) May 24, 2024
- Nallathamby Lab’s Kevin Armknecht is Invited to Present at the Midwest Microscopy and Microanalysis Workshop 2024 May 7, 2024
Archives
Categories
NIH Funding Opportunities
- NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed) January 3, 2025Funding Opportunity PAR-25-089 from the NIH Guide for Grants and Contracts. This NOFO invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted […]
- Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Coordinating Center (U01 Clinical Trial Required) January 3, 2025Notice NOT-HG-25-016 from the NIH Guide for Grants and Contracts
- Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Clinical Sites (U01, Clinical Trial Required) January 3, 2025Notice NOT-HG-25-015 from the NIH Guide for Grants and Contracts
- Notice of change in "Funding Opportunity Goals" for RFA-EY-25-001 "BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)" January 3, 2025Notice NOT-EY-25-004 from the NIH Guide for Grants and Contracts
- Notice of Change: NIDA Participation in RFA-EY-25-001: BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) January 3, 2025Notice NOT-DA-24-064 from the NIH Guide for Grants and Contracts
- NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required) January 3, 2025Funding Opportunity PA-25-147 from the NIH Guide for Grants and Contracts. This NOFO invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities […]
- Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) January 3, 2025Funding Opportunity PAR-25-329 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support the discovery and development of medications to prevent and treat substance use disorders (SUDs) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a […]
- Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) January 3, 2025Funding Opportunity PAR-25-328 from the NIH Guide for Grants and Contracts. The purpose of this notice of Funding Opportunity (NOFO) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund […]
- Pre-Application Webinar for RFA-NR-25-003: Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional) January 3, 2025Notice NOT-NR-25-009 from the NIH Guide for Grants and Contracts
- Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35) January 2, 2025Funding Opportunity PA-25-280 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grants (T35) to eligible, domestic institutions to develop and/or enhance research training opportunities for predoctoral students interested in careers within biomedical, behavioral, or clinical […]
Recent Comments